Erenumab

Migraine Prophylaxis

Migraine Prophylaxis Indicated for preventive treatment of migraines 70 mg SC once monthly Some patients may need 140 mg SC once monthly (administered as 2 consecutive 70-mg SC doses)

Renal impairment Mild-to-moderate: Clinical studies did not reveal a difference in pharmacokinetics Severe (eGFR <30 mL/min/1.73 m²): Not studied

Hypersensitivity to drug or excipients

Hypersensitivity reactions (eg, rash, angioedema, anaphylaxis) reported; may occur within hours or one week following administration; discontinue administration and initiate appropriate therapy if serious reaction occurs

Not Classi Pregnancy Data are not available regarding fetal risk if used in pregnant women Animal studies No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation Clinical considerations Data suggest that women with migraine may be at increased risk of preeclampsia during pregnancy Lactation Data are not available on the presence in human milk, the effects on the breastfed infant, or the effects on milk production Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

1-10% Injection site pain (5-6%) Constipation (1-3%) Cramps, muscle spasms (<3%)

Human monoclonal antibody; binds to the calcitonin gene-related peptide (CGRP) receptor, which is thought to be causally involved in migraine pathophysiology